Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Out-licensing
- View
New Novel Treatment for Osteoporosis
We are currently seeking a company to buy or partner and market BONISARA - a Novel Treatment for Osteoporosis
Mechanism of action
Reduces bone resorption and builds bone tissue
Full description
BONISARA, which contains strontium gluconate, is the only product in the US that decreases bone resorption and stimulates the formation of new bone tissue (the bisphosphonates do not build bone tissue), reducing the risk of vertebral fractures in patients with osteoporosis. We are currently seeking a company to purchase the product or partner to market the product in the US.
Development status
Registered
Patent information
3 US Patents pending.
Type of business relationship sought
We are seeking a partner to either purchase the product or market the product in the US.
Licensing contact
Robert Moscato
General Manager
General Manager
More information
For more information about the product please visit website.
Company details
TRx Pharma
TRx Pharma is a specialty pharmaceutical company focused on acquiring, marketing, developing and outlicensing therapies for metabolic and chronic inflammation diseases.
TRx Pharma is a specialty pharmaceutical company focused on acquiring, marketing, developing and outlicensing therapies for metabolic and chronic inflammation diseases.
Related reports
Are you looking for reports related to this particular subject. Our Reports section is the best place to start.
Related items
Related categories
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us